Insider buying last 90 days
No open-market insider purchases were filed for SYRE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SYRE insider filing, plotted on the chart in Gekko.Open SYRE in Gekko
NASDAQ: SYRE
Spyre Therapeutics (SYRE) Stock Analysis & Forecast
Sep 28 close
$85.79+0.10 (+0.1%)
Gekko Brief
AI summaryThis week's coverage of Spyre Therapeutics (SYRE) consists mainly of comparison pieces and general financial-data summaries, including a head-to-head look against Gain Therapeutics and overviews of its income statement and price-to-cash-flow metrics, with no company-specific results, guidance or regulatory news reported.
SYRE closed at $85.79, sitting between its 50-day average of $96.82 and 200-day average of $66.52, reflecting a mixed trend picture. Over the past month the stock is down 8.4%, though it remains up 81.3% over six months and 449.6% over the past year. The GekkoIndex reads 66.3, placing SYRE in the Accumulation zone, up 4.9 over the past five sessions. Shares trade 12% below Gekko Fair Value of $97.44.
The next earnings report is scheduled for 3 November 2026, 35 days out and beyond a typical 20-trading-day holding window; the prior report on 4 August showed an EPS of -0.36 against a -0.76 estimate, with a 9.9% reaction, and the company has beaten estimates in 6 of the last 8 quarters. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged a 14.9% return over 5 years, rising in 4 of them. Analyst consensus stands at 12 buy and 1 hold among 13 firms, with a consensus target of $120.08.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Spyre Therapeutics price vs fair value
Close $85.79200-day averageGekko Fair Value $97.44
Spyre Therapeutics quick facts
- Market cap
- $7.45B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.90
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 3.00
- Volume
- 1.05M avg 1.26M
- 1-year return
- +449.6%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±15.8%
- 50-day average
- $96.82
- 200-day average
- $66.52
- Next earnings
- Nov 3
- Shares outstanding
- 88.17M
Spyre Therapeutics swing-trade checklist
Spyre Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $85.79 sits between the 50-day ($96.82) and 200-day ($66.52) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.3, Accumulation
Reading 66.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
12.0% below
Price is 12% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+14.9% on average
From this point in the calendar, the next 20 trading days averaged +14.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Spyre Therapeutics stock chart and price history
Spyre Therapeutics closed at $85.79 on Sep 28, 2026, +449.6% over the past year, inside a 52-week range of $15.49 to $110.18.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.4%
- 3 months
- −4.8%
- 6 months
- +81.3%
- 1 year
- +449.6%
The full SYRE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SYRE in Gekko
Follow Spyre Therapeutics through every session
Put SYRE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SYRE in GekkoFree for 7 days. No credit card required.
About Spyre Therapeutics
Spyre Therapeutics works on early, preclinical research aimed at treating inflammatory bowel disease, covering conditions such as ulcerative colitis and Crohn's disease. Its work centers on antibody-based candidates designed to act on specific biological targets involved in the disease, including one built to bind the a4ß7 integrin and another aimed at tumor necrosis factor-like ligand 1A. The company is best known for pursuing these antibody programs rather than for any product currently available to patients.
Spyre's pipeline extends beyond its lead candidates to include several other antibody therapies, some combining more than one mechanism of action, such as pairing anti-a4ß7 with anti-IL-23 activity, or joining anti-TL1A with anti-IL-23 components. Other candidates target IL-23 alone or use mechanisms described as novel. All of these programs remain in preclinical evaluation, meaning the company's work at this stage is research-driven rather than commercial, with no indication of existing customers or revenue-generating products.
The company was originally incorporated in 2013 under the name Aeglea BioTherapeutics, Inc., adopting the name Spyre Therapeutics, Inc. in November 2023. It is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ under the ticker SYRE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- spyre.com
Spyre Therapeutics GekkoIndex: the smart money zone
Spyre Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.3, in the Accumulation zone, up 4.9 points over five sessions.
66.3Accumulation
Up 4.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 34 | +4.5% | +14.3% |
| Accumulation (current zone) | 170 | +1.2% | +4.9% |
| Neutral | 408 | +1.6% | +7.4% |
| Distribution | 48 | −0.1% | −2.0% |
| Selling | 12 | +0.8% | −8.0% |
Average SYRE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SYRE price, zone by zone.Track SYRE in Gekko
Is Spyre Therapeutics stock overvalued? Gekko Fair Value
Spyre Therapeutics trades 12.0% below Gekko Fair Value of $97.44, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Spyre Therapeutics shares are worth, recalculated every trading day.
$97.44
Gekko Fair Value, Sep 26, 2026
12.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open SYRE in Gekko
Spyre Therapeutics insider and Congress trading
No open-market insider purchases were filed for Spyre Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SYRE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SYRE, plotted on the chart in Gekko.Open SYRE in Gekko
Buybacks
Spyre Therapeutics has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2025
- $117K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold SYRE.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Spyre Therapeutics earnings: next date and track record
Spyre Therapeutics reports on Nov 3, 2026 (35 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
35 days away
- EPS estimate
- −$0.80
6 of 8reports beat the EPS estimate
±7.2%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.36 est −$0.76 | — | +9.9% |
| May 5, 2026 | −$0.74 est −$0.64 | — | +5.6% |
| Feb 19, 2026 | −$0.74 est −$0.80 | $90.49M est $142.9M | +18.1% |
| Nov 4, 2025 | −$0.15 est −$0.68 | — | −3.9% |
| Aug 5, 2025 | −$0.49 est −$0.73 | — | −1.2% |
| May 8, 2025 | −$0.60 est −$0.84 | — | +10.9% |
| Feb 28, 2025 | −$0.81 est −$0.89 | — est $3.00M | −2.3% |
| Nov 7, 2024 | −$1.36 est −$0.82 | — est $2.63M | +5.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Spyre Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Spyre Therapeutics is $120.08, +40.0% from the last close, from 13 firms rating the stock in the last 90 days.
$120.08consensus 12-month target, +40.0% from the last close
Now $85.79Avg $120.08
Low $115High $130
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 27 | JonesTrading | $121 | +41.0% |
| Sep 9 | Wedbush | $123 | +43.4% |
| Sep 9 | Leerink Partners | $128 | +49.2% |
| Sep 9 | Jefferies | $126 | +46.9% |
| Sep 8 | LifeSci Capital | $116 | +35.2% |
+4.9%average 20-day move after past Accumulation readings
+14.9%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Spyre Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Spyre Therapeutics averaged +14.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.5% | 2 of 5 |
| Next 10 trading days | +7.8% | 4 of 5 |
| Next 15 trading days | +15.4% | 4 of 5 |
| Next 20 trading days | +14.9% | 4 of 5 |
| Next 30 trading days | +46.7% | 3 of 5 |
For scale, SYRE’s typical 20-trading-day move in either direction is about 15.8%.
Spyre Therapeutics market cap and key statistics
Spyre Therapeutics’s market cap is $7.45B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $7.45B
- EPS, TTM
- −$1.90
- Gekko Fair Value
- $97.44
Trading
- Volume
- 1.05M
- Avg volume, 20 days
- 1.26M
- 52-week high
- $110.18
- 52-week low
- $15.49
- Shares outstanding
- 88.17M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -23%
- Quarterly earnings growth, YoY
- −99.7%
Risk and income
- Beta
- 3.00
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±15.8%
Spyre Therapeutics stock news this week
Coverage of Spyre Therapeutics this week reads neutral: 1 positive, 3 neutral and 0 negative headlines.
- Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head ComparisonDefense World, Sep 28
- Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and historyYahoo Finance Australia, Sep 24
- Spyre Therapeutics, Inc Income Statement – MUN:3920TradingView, Sep 22
- Equity in earnings of Spyre Therapeutics, Inc – MUN:3920TradingView, Sep 22
- Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920TradingView, Sep 21
Spyre Therapeutics peers
Spyre Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Spyre Therapeutics stock FAQ
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $7.45B at the Sep 28, 2026 close of $85.79, with 88.17M shares outstanding.
What is the Spyre Therapeutics stock forecast?
The consensus analyst 12-month price target for Spyre Therapeutics is $120.08, +40.0% from the last close. Of the 13 firms that rated the stock in the last 90 days, 12 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Spyre Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Spyre Therapeutics is undervalued: the Sep 28, 2026 close of $85.79 is 12.0% below Gekko Fair Value of $97.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Spyre Therapeutics report earnings next?
Spyre Therapeutics is expected to report on Nov 3, 2026 (35 days away). Analysts expect earnings of −$0.80 per share. Spyre Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 7.2% on average across the report.
What is Spyre Therapeutics’s 52-week high and low?
Spyre Therapeutics’s 52-week high is $110.18 and its 52-week low is $15.49; it closed at $85.79 on Sep 28, 2026, +449.6% over the past year. Over the last five years the shares peaked at $212.50 on Oct 6, 2021.
Is Spyre Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Spyre Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.